Pediatric Hematology Oncology Journal · Published 2026-06-30 · DOI 10.1016/j.phoj.2026.100859
Uzma Imam, Ammara Hameed, Wajiha Aijaz, Meher Afroze, Arit Parkash
Background: Immunoproliferative small intestinal disease (IPSID) and Mucosa-associated lymphoid tissue (MALT) lymphoma are both rare in the pediatric population. These are low grade indolent conditions, both related to the exposure to certain infections. The presumptive progression of IPSID to duodenal and jejunal MALT lymphoma is a rare phenomenon, and may be associated with increased chances of transforming into more malignant tumors like Diffuse Large B cell lymphoma (DLBCL). Case report: We present the case of a 12 year old female who presented with IPSID and was treated with a prolonged course of metronidazole and amoxicillin-clavulanate. A repeat endoscopy and biopsy 5 months later when symptoms failed to improve confirmed duodenal-jejunal MALT lymphoma. The patient then received six cycles of rituximab and alkylating agent-based chemotherapy (R-CHOP), and following normalization of lesions on PET-CT scan, remains in remission six months following completion of treatment. Conclusion: In areas with a high infectious burden, rare conditions like IPSID and MALT lymphoma should remain on the differential diagnosis list when pediatric patients present with chronic abdominal pain and dyspepsia.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Imam, U., Hameed, A., Aijaz, W., et al. (2026). Pediatric IPSID evolving into duodeno jejunal MALT lymphoma: a case report. Pediatric Hematology Oncology Journal. https://doi.org/10.1016/j.phoj.2026.100859